Target Price | $80.33 |
Price | $58.09 |
Potential |
38.29%
register free of charge
|
Number of Estimates | 9 |
9 Analysts have issued a price target Verona Pharma plc Sponsored ADR 2026 .
The average Verona Pharma plc Sponsored ADR target price is $80.33.
This is
38.29%
register free of charge
$93.00
60.10%
register free of charge
$72.00
23.95%
register free of charge
|
|
A rating was issued by 9 analysts: 9 Analysts recommend Verona Pharma plc Sponsored ADR to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Verona Pharma plc Sponsored ADR stock has an average upside potential 2026 of
38.29%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 42.30 | 313.53 |
641.20% | ||
EBITDA Margin | -363.19% | 33.54% |
109.23% | ||
Net Margin | -426.15% | 2.96% |
100.69% |
9 Analysts have issued a sales forecast Verona Pharma plc Sponsored ADR 2025 . The average Verona Pharma plc Sponsored ADR sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Verona Pharma plc Sponsored ADR 2025 . The average Verona Pharma plc Sponsored ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 Verona Pharma plc Sponsored ADR Analysts have issued a net profit forecast 2025. The average Verona Pharma plc Sponsored ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -2.13 | 0.11 |
208.70% | 105.16% | |
P/E | 529.69 | |
EV/Sales | 14.80 |
3 Analysts have issued a Verona Pharma plc Sponsored ADR forecast for earnings per share. The average Verona Pharma plc Sponsored ADR EPS is
This results in the following potential growth metrics and future valuations:
Verona Pharma plc Sponsored ADR...
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
Wells Fargo |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
Canaccord Genuity |
Locked
➜
Locked
|
Locked | Feb 12 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 21 2025 |
Roth MKM |
Locked
➜
Locked
|
Locked | Jan 10 2025 |
Truist Securities |
Locked
➜
Locked
|
Locked | Jan 08 2025 |
Wells Fargo |
Locked
➜
Locked
|
Locked | Jan 08 2025 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 28 2025 |
Locked
Wells Fargo:
Locked
➜
Locked
|
Feb 28 2025 |
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Feb 12 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 21 2025 |
Locked
Roth MKM:
Locked
➜
Locked
|
Jan 10 2025 |
Locked
Truist Securities:
Locked
➜
Locked
|
Jan 08 2025 |
Locked
Wells Fargo:
Locked
➜
Locked
|
Jan 08 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.